Kirsty (Insulin Aspart)

Insulin Aspart binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that move glucose‑transport proteins to the cell surface. This promotes rapid uptake of glucose from the bloodstream and suppresses liver glucose production, resulting in a quick reduction of blood sugar after injection.

The dose of Kirsty is individualized by the prescribing healthcare professional. It is based on factors such as the patient’s current blood‑glucose patterns, carbohydrate intake, physical activity, renal function and other medications. Patients should follow the prescriber’s instructions and adjust only under medical guidance.

Insulin Aspart is classified as a pregnancy category that should be used only when the expected benefit to the mother outweighs potential risks to the fetus. Limited data are available for breastfeeding, but insulin analogues are generally considered compatible with nursing when clinically required. Consultation with a healthcare provider is essential.

To order Kirsty, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Kirsty (insulin aspart) has a faster onset and earlier peak compared with regular human insulin, similar to other rapid‑acting analogues such as insulin lispro and insulin glulisine. Clinical studies show comparable efficacy in post‑prandial glucose control, with a slightly lower risk of late‑post‑prandial hypoglycemia for some patients.

Kirsty should be stored in a refrigerator at 2‑8 °C, protected from light, and kept in its original packaging to avoid moisture. Do not freeze or shake the product. Once in use, the vial or pen may be kept at controlled room temperature (up to 30 °C) for a limited period, as indicated on the label.

Kirsty is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. It is usually injected shortly before meals, often within 5–10 minutes, to match the rise in blood glucose from food. The exact timing and injection technique should follow the prescriber’s instructions and patient‑education guidelines.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from urticaria to anaphylaxis. Rarely, patients may develop insulin antibodies that alter drug action. Prompt recognition and treatment of these events are critical, and patients should be educated on emergency measures.

Kirsty should not be used by individuals with a known hypersensitivity to insulin aspart or any of the excipients in the formulation. It is also contraindicated in patients experiencing severe hypoglycemia until the condition is corrected, and in those with certain endocrine disorders where rapid‑acting insulin is inappropriate without specialist supervision.